AHSNs in England have supported the rollout of two innovations under the Accelerated Access Collaborative’s Rapid Uptake Products Programme – FeNO, a point of care test to help diagnose asthma, and biologic therapies, NICE-approved treatments for patients with severe asthma which does not respond to regular treatments. Both innovations had lower than expected uptake, presenting an opportunity to improve take-up and support the NHS Long Term Plan ambition of improving early and accurate diagnosis of respiratory conditions by embedding both FeNO testing and asthma biologics into localised clinical pathways.
Led by Oxford AHSN (Asthma Biologics) and Wessex AHSN (FeNO), the programmes aimed to improve patient care and outcomes through enhanced access to diagnostics and treatments for severe asthma. Both programmes focused on collaboration at a national, regional and local level across healthcare systems, industry partners, patients, and the community and voluntary sector to integrate FeNO testing and access to asthma biologics into everyday clinical practice.
AHSNs worked within their individual systems to support asthma pathway improvements by taking a pathway-based transformation approach. AHSNs provided clinical and transformation leadership, shared best practice, and developed education and implementation materials for those involved in providing asthma care.
A package of educational resources for each innovation, including information documents, podcasts, posters, learning modules and webinars, was created to support clinicians. The toolkits were designed in a practical way to support teams adopting and sustaining the use of FeNO and asthma biologics.